药明合联(02268)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02268 药明合联

休市中 12-08 16:08:40

28.800

-0.450

-1.54%

最高29.300	最低28.450	成交量93.73万
今开28.950	昨收29.250	日振幅2.91%
总市值339.39亿	流通市值339.39亿	总股本11.78亿
成交额2,689万	换手率0.08%	流通股本11.78亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02268","market":"HK","secType":"STK","nameCN":"药明合联","latestPrice":28.8,"timestamp":1702022920031,"preClose":29.25,"halted":0,"volume":937310,"delay":0,"floatShares":1178446000,"shares":1178446000,"eps":0.19198906,"marketStatus":"休市中","marketStatusCode":7,"change":-0.45,"latestTime":"12-08 16:08:40","open":28.95,"high":29.3,"low":28.45,"amount":26889990,"amplitude":0.02906,"askPrice":28.8,"askSize":14500,"bidPrice":28.65,"bidSize":11000,"shortable":0,"etf":0,"ttmEps":0.2448760768846262,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1702258200000},"adr":0,"listingDate":1700150400000,"adjPreClose":29.25,"volumeRatio":0.20073794877173598,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02268","defaultTab":"news","newsList":[{"id":"2389079365","title":"2天股价跌超30%！千亿生物药巨头，神操作反转","url":"https://stock-news.laohu8.com/highlight/detail?id=2389079365","media":"深蓝财经","top":-1,"share":"https://www.laohu8.com/m/news/2389079365?lang=zh_cn&edition=full","pubTime":"2023-12-07 18:42","pubTimestamp":1701945720,"startTime":"0","endTime":"0","summary":"12月4日，千亿生物药巨头药明生物官网，发布了一份16页的业务更新PPT。12月4日、5日，其股价分别跌去了23.79%、8.45%，两天股价跌超3成。2022年，药明生物营收152.7亿元，同比增长48.38%；归母净利润为44.20亿元，同比增长30.45%。2“自爆”前不久，药明生物分拆出3年来港股最大生物医药IPO。今年7月，药明生物发公告，宣布分拆药明合联赴港上市。截至12月6日收盘，其股价自上市以来已累计涨了44.9%，市值达351.77亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzU1Njc1NjA2NA==&mid=2247571673&idx=3&sn=e5da1cfe07803fab73f185c7d43ce10f&chksm=fbc3a5d6ccb42cc0aaa4043c922b57e779b83cb24031ff9decc7f69f321abda87cb21d759072#rd","is_publish_highlight":false},{"id":"2389209594","title":"中信证券：首予药明合联(02268)“买入”评级 目标价39港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2389209594","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2389209594?lang=zh_cn&edition=full","pubTime":"2023-12-07 09:09","pubTimestamp":1701911366,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中信证券发布研究报告称，首予药明合联“买入”评级，预计2023-25年经调整净利润/核心净利润分别为3.79亿元/6.54亿元/10.49亿元，对应每股经调整EPS预测分别为0.32/0.56/0.89元，目标价39港元。公司是全球领先的XDCCRDMO，端到端服务能力出色，2022年全球分子市占率近35%;伴随客户研发管线增长和终端放量，公司业绩有望迎来爆发式增长。该行认为ADC外包服务市场将更多地集中于少数核心企业手中，市场份额的集中度有望超过抗体药物市场。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1034720.html","is_publish_highlight":false},{"id":"2389370926","title":"港股通调整预测：药明合联、中国恒大等19股有望纳入","url":"https://stock-news.laohu8.com/highlight/detail?id=2389370926","media":"观点地产网","top":-1,"share":"https://www.laohu8.com/m/news/2389370926?lang=zh_cn&edition=full","pubTime":"2023-12-06 11:11","pubTimestamp":1701832289,"startTime":"0","endTime":"0","summary":"观点网讯：据LiveReport大数据，截至2023年12月5日，预计调入港股通的市值门槛约为61.55亿港元，预计调出港股通的市值线约为42.25亿港元。截至2023年12月5日，未来有可能进入港股通的股票有19只，分别为：药明合联、友宝在线、锅圈、十月稻田、中旭未来、第四范式、宜明昂科-Ｂ、巨星传奇、科伦博泰生物-Ｂ、恒大物业、沧港铁路、中国春来、粤丰环保、旭辉控股集团、中国恒大、恒大汽车、世茂集团、神威药业、恒隆集团。相关个股有望于2024年3月4日获得正式纳入。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202312061111328233c2a2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202312061111328233c2a2&s=b","is_publish_highlight":false},{"id":"2389057017","title":"港股通调整预测：药明合联、科伦博泰等19股有望纳入，这14只港股危险了！","url":"https://stock-news.laohu8.com/highlight/detail?id=2389057017","media":"财华社","top":-1,"share":"https://www.laohu8.com/m/news/2389057017?lang=zh_cn&edition=full","pubTime":"2023-12-06 10:15","pubTimestamp":1701828946,"startTime":"0","endTime":"0","summary":"12月4日，港股通标的名单发生调整，KEEP正式调入港股通，当日股价大跌27.56%，颇有一种“利好落地即利空”的样子。","market":"hk","thumbnail":"https://images.finet.hk/photoLib/title/202312_1/72bdd05d-246e-4a93-81ea-36451d882d0a.jpg","type":0,"news_type":0,"thumbnails":["https://images.finet.hk/photoLib/title/202312_1/72bdd05d-246e-4a93-81ea-36451d882d0a.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.finet.hk/newscenter/news_content/656fd952bde0b375aabeaf3c","is_publish_highlight":false},{"id":"2389703921","title":"药明系早盘走高 药明合联及药明巨诺-B均涨逾5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2389703921","media":"新浪港股","top":-1,"share":"https://www.laohu8.com/m/news/2389703921?lang=zh_cn&edition=full","pubTime":"2023-12-06 10:01","pubTimestamp":1701828100,"startTime":"0","endTime":"0","summary":"药明系早盘走高，药明合联（02268）上涨5.28%，报28.90港元；药明巨诺-B（02126）上涨4.70%，报3.12港元；药明生物（02269）上涨3.30%，报31.35港元；药明康德（02359）上涨1.73%，报82.40港元。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2023-12-06/doc-imzwztse2794779.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2023-12-06/doc-imzwztse2794779.shtml","is_publish_highlight":false},{"id":"2389703643","title":"药明合联(02268)上涨5.1%，报28.85元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2389703643","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2389703643?lang=zh_cn&edition=full","pubTime":"2023-12-06 09:38","pubTimestamp":1701826730,"startTime":"0","endTime":"0","summary":"12月6日，药明合联(02268)盘中上涨5.1%，截至09:38，报28.85元/股，成交807.74万元。药明合联生物技术有限公司是一家专注于提供包括抗体药物偶联物(ADC)在内的生物偶联药物研究、开发与制造服务的合同研究开发及制造组织(CRDMO)，具有全面的跨学科服务能力和专业知识。根据2022年弗若斯特沙利文的报告，该公司是全球第二大ADC等生物偶联药物CRDMO，市场份额从2020年的1.8%增长至2022年的9.8%，显示出迅速的业务拓展和市场占有率的提升。截至2023年中报，药明合联营业总收入9.93亿元、净利润1.77亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2023/12/06093838681367.shtml","is_publish_highlight":false},{"id":"2389177456","title":"四季度以来港股IPO市场持续回暖 尚有近百家企业交表排队","url":"https://stock-news.laohu8.com/highlight/detail?id=2389177456","media":"中国经济网","top":-1,"share":"https://www.laohu8.com/m/news/2389177456?lang=zh_cn&edition=full","pubTime":"2023-12-06 07:27","pubTimestamp":1701818820,"startTime":"0","endTime":"0","summary":"此外，目前近百家企业交表排队，预计一批企业将在年末、明年一季度密集上市。　　进入四季度以来，回暖信号持续释放。药明合联募资36.76亿港元，位列今年港股IPO募资额第三名。　　投资者对港股IPO情绪有所改善。　　此外，中东资金亦有望成为港股IPO市场的增量资金。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2023-12-06/doc-imzwzpka6151387.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2023-12-06/doc-imzwzpka6151387.shtml","is_publish_highlight":false},{"id":"2389416791","title":"药明生物今年药物开发、药物生产业绩均不及预期，药明合联收入预期不变","url":"https://stock-news.laohu8.com/highlight/detail?id=2389416791","media":"IPO早知道","top":-1,"share":"https://www.laohu8.com/m/news/2389416791?lang=zh_cn&edition=full","pubTime":"2023-12-05 12:09","pubTimestamp":1701749344,"startTime":"0","endTime":"0","summary":"公司称，药物开发（D端）新增项目数减少导致3亿美元收入的减少，及药物生产（M端）收入递延带来1亿美元收入降低，是今年不及预期的主要原因。分业务来看，公司药物开发收入下调18%-20%；药物生产收入下降15%-18%；而药物发现（R端）业务和药明合联预期不变。ADC需求增长强劲另外，药明生物预计其并表子公司药明合联2023和2024年收入分别有70%-75%和60%-65%的增长。截至2023年上半年，药明合联在中国拥有所有中美双报IND/BLA的ADC候选药物的开发合同。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2023/12/05120938670745.shtml","is_publish_highlight":false},{"id":"2389793618","title":"11月IPO市场：港股新股零破发！FINI能否进一步带动市场回暖？","url":"https://stock-news.laohu8.com/highlight/detail?id=2389793618","media":"财华社","top":-1,"share":"https://www.laohu8.com/m/news/2389793618?lang=zh_cn&edition=full","pubTime":"2023-12-05 10:32","pubTimestamp":1701743525,"startTime":"0","endTime":"0","summary":"2023年1-11月，港股市场累计56只新股上市(不含转板)，募资371.89亿港元；美股市场累计234只新股上市，募资265.16亿美元；A股市场累计292只新股上市，募资3415.37亿人民币。","market":"hk","thumbnail":"https://images.finet.hk/photoLib/title/202312_1/0de7b6da-9f22-4050-bfae-58d157034990.jpg","type":0,"news_type":0,"thumbnails":["https://images.finet.hk/photoLib/title/202312_1/0de7b6da-9f22-4050-bfae-58d157034990.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.finet.hk/newscenter/news_content/656e8ba5bde0b375aabeaf2c","is_publish_highlight":false},{"id":"2388789105","title":"药明合联12月04日主力资金流出858万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2388789105","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2388789105?lang=zh_cn&edition=full","pubTime":"2023-12-04 16:16","pubTimestamp":1701677799,"startTime":"0","endTime":"0","summary":"12月04日, 药明合联股价跌10.87%，报收28.70元，成交金额2.26亿元，换手率0.64%，振幅18.79%，量比3.68。药明合联今日主力资金净流出858万元，连续3日净流出，上一交易日主力净流入2612万元。该股近5个交易日下跌2.23%，主力资金累计净流入1477万元；近20日主力资金累计净流入2402万元，其中净流入天数为4日。该股主力净额占比0.03%，港股市场排名2482/2615。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023120416182183ce7728&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023120416182183ce7728&s=b","is_publish_highlight":false},{"id":"2388207717","title":"药明还是把自己“作”渡劫了","url":"https://stock-news.laohu8.com/highlight/detail?id=2388207717","media":"瞪羚社","top":-1,"share":"https://www.laohu8.com/m/news/2388207717?lang=zh_cn&edition=full","pubTime":"2023-12-04 14:08","pubTimestamp":1701670080,"startTime":"0","endTime":"0","summary":"聚焦高成长项目，80000+投资菁英共同关注      药明生物正在经历市场重大质疑。      12月4日早，药明生物更新最新业务进展：2023年公司收入预计增长10%（剔除新冠增长36%），而利....","market":"hk","thumbnail":"https://inews.gtimg.com/news_ls/OBMEa-6wsIMZ7wpLvtpswVzrwq3CMSqTtLU_P7c_KDVykAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/news_ls/OBMEa-6wsIMZ7wpLvtpswVzrwq3CMSqTtLU_P7c_KDVykAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20231204A04F5R00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20231204A04F5R00","is_publish_highlight":false},{"id":"2388277556","title":"药明合联(02268)下跌10.56%，报28.8元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2388277556","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2388277556?lang=zh_cn&edition=full","pubTime":"2023-12-04 09:34","pubTimestamp":1701653687,"startTime":"0","endTime":"0","summary":"12月4日，药明合联(02268)盘中下跌10.56%，截至09:34，报28.8元/股，成交1549.12万元。药明合联生物技术有限公司是一家专注于提供包括抗体药物偶联物(ADC)在内的生物偶联药物研究、开发与制造服务的合同研究开发及制造组织(CRDMO)，具有全面的跨学科服务能力和专业知识。根据2022年弗若斯特沙利文的报告，该公司是全球第二大ADC等生物偶联药物CRDMO，市场份额从2020年的1.8%增长至2022年的9.8%，显示出迅速的业务拓展和市场占有率的提升。截至2023年中报，药明合联营业总收入9.93亿元、净利润1.77亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2023/12/04093438652525.shtml","is_publish_highlight":false},{"id":"2388288706","title":"【次新异动】药明合联(02268)冲高逾11% 机构指ADC行业高景气 料其市场份额持续提高","url":"https://stock-news.laohu8.com/highlight/detail?id=2388288706","media":"凤凰网港股","top":-1,"share":"https://www.laohu8.com/m/news/2388288706?lang=zh_cn&edition=full","pubTime":"2023-12-01 14:32","pubTimestamp":1701412337,"startTime":"0","endTime":"0","summary":"金吾财讯 | 药明合联 持续强势，午后升幅进一步扩大，截至发稿，报31.75港元，涨11.01%，成交额1.42亿港元。民生证券表示，药明合联具有行业领先的技术实力和综合能力，布局全球产能为需求激增的偶联药行业提供更强大赋能。该行指，ADC行业高景气，药明合联作为全球龙头持续提高市场份额。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=de70773e1555178ed38ffcc73a07e998","is_publish_highlight":false},{"id":"2388401665","title":"药明合联现涨逾7% 较招股价涨超48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2388401665","media":"新浪港股","top":-1,"share":"https://www.laohu8.com/m/news/2388401665?lang=zh_cn&edition=full","pubTime":"2023-12-01 11:30","pubTimestamp":1701401416,"startTime":"0","endTime":"0","summary":"药明合联（02268）早盘持续走高，上涨6.99%，现报30.60港元，盘中创上市新高，较招股价已涨超48%，成交额1986.212万港元。\n　　药明合联于11月17日挂牌上市，公告显示，公司发行1.78亿股股份，每股定价20.6港元，每手500股，所得款项净额约34.83亿港元。公司分拆自药明生物，是专注于全球抗体药物偶联物（ADC）及更广泛生物偶联药物市场的领先合同研究、开发及制造组织（CRDMO），亦是一家致力于提供全面综合服务的公司。\n\n股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2023-12-01/doc-imzwnqia0906310.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2023-12-01/doc-imzwnqia0906310.shtml","is_publish_highlight":false},{"id":"2388405394","title":"港股异动 | 药明合联(02268)现涨超5% 较招股价涨超46% 公司为全球ADC CDMO市占率第二的供应商","url":"https://stock-news.laohu8.com/highlight/detail?id=2388405394","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2388405394?lang=zh_cn&edition=full","pubTime":"2023-12-01 10:03","pubTimestamp":1701396227,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，药明合联现涨超5%，盘中高见30.25港元，创上市新高，较招股价已涨超46%。截至发稿，涨5.42%，报30.15港元，成交额5412.06万港元。据悉，药明合联于11月17日挂牌上市，公告显示，公司发行1.78亿股股份，每股定价20.6港元，每手500股，所得款项净额约34.83亿港元。药明合联财务表现优异，2020至2022年营收复合增速达220.61%，经调整净利润复合增速达143.52%。公司作为全球ADC CDMO市占率第二的供应商，有望随着ADC药物行业蓬勃发展实现快速成长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1032016.html","is_publish_highlight":false},{"id":"2388210403","title":"药明合联(02268)上涨5.24%，报30.1元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2388210403","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2388210403?lang=zh_cn&edition=full","pubTime":"2023-12-01 09:52","pubTimestamp":1701395548,"startTime":"0","endTime":"0","summary":"12月1日，药明合联(02268)盘中上涨5.24%，截至09:52，报30.1元/股，成交4327.12万元。药明合联生物技术有限公司是一家专注于提供包括抗体药物偶联物(ADC)在内的生物偶联药物研究、开发与制造服务的合同研究开发及制造组织(CRDMO)，具有全面的跨学科服务能力和专业知识。根据2022年弗若斯特沙利文的报告，该公司是全球第二大ADC等生物偶联药物CRDMO，市场份额从2020年的1.8%增长至2022年的9.8%，显示出迅速的业务拓展和市场占有率的提升。截至2023年中报，药明合联营业总收入9.93亿元、净利润1.77亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2023/12/01095238634654.shtml","is_publish_highlight":false},{"id":"2387467100","title":"投资者速看！100+质优上市公司集中正向路演，活动报名中！","url":"https://stock-news.laohu8.com/highlight/detail?id=2387467100","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2387467100?lang=zh_cn&edition=full","pubTime":"2023-11-30 09:54","pubTimestamp":1701309276,"startTime":"0","endTime":"0","summary":"在为期三天的大会活动中，我们共设置了四大主题版块：1.“第八届智通财经资本市场年会暨上市公司颁奖典礼”、2.“智通财经新春策略会”、3.2023 中资海外基金高峰论坛暨海外基金新智奖颁奖典礼、4.金中环论坛（香港）。作为大会主旋律之一的 “智通财经新春策略会”活动将分别于12月6日下午至12月7日（全天）举行。届时，将有100+港、美、A股上市公司集中正向路演。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1031312.html","is_publish_highlight":false},{"id":"2387100036","title":"药明合联11月29日遭主力抛售206万元 环比增加182.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2387100036","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2387100036?lang=zh_cn&edition=full","pubTime":"2023-11-29 16:15","pubTimestamp":1701245731,"startTime":"0","endTime":"0","summary":"11月29日, 药明合联股价跌0.69%，报收28.75元，成交金额4600万元，换手率0.14%，振幅4.15%，量比1.09。药明合联今日主力资金净流出206万元，连续4日净流出，上一交易日主力净流出73万元，今日环比增加182.19%。该股近5个交易日上涨2.51%，主力资金累计净流入88万元；近20日主力资金累计净流入647万元，其中净流入天数为3日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202311291616248217c0a5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202311291616248217c0a5&s=b","is_publish_highlight":false},{"id":"2387171941","title":"CXO行业周报：板块表现分化 ADC保持高景气度","url":"https://stock-news.laohu8.com/highlight/detail?id=2387171941","media":"财通证券股份有...","top":-1,"share":"https://www.laohu8.com/m/news/2387171941?lang=zh_cn&edition=full","pubTime":"2023-11-29 00:00","pubTimestamp":1701187200,"startTime":"0","endTime":"0","summary":"本周行情回顾：本周沪深300 跌幅0.84%，申万医疗研发外包指数跌幅2.59%，跑输大盘1.75pct, 我们根据行业重点跟踪公司建立的CXO 行业组合本周平均跌幅2.3%，因此整体CXO 板块本周热度有所回落。药明合联财务表现优异，2020 至2022 年营收复合增速达220.61%，经调整净利润复合增速达143.52%。公司作为全球ADC CDMO市占率第二的供应商，有望随着ADC 药物行业蓬勃发展实现快速成长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023112910204982167136&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023112910204982167136&s=b","is_publish_highlight":false},{"id":"2386197834","title":"药明合联11月28日主力资金流出73万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2386197834","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2386197834?lang=zh_cn&edition=full","pubTime":"2023-11-28 16:16","pubTimestamp":1701159412,"startTime":"0","endTime":"0","summary":"11月28日, 药明合联股价跌0.86%，报收28.95元，成交金额2418万元，换手率0.07%，振幅1.71%，量比0.32。药明合联今日主力资金净流出73万元，连续3日净流出，上一交易日主力净流出0万元。该股近5个交易日上涨4.70%，主力资金累计净流入423万元；近20日主力资金累计净流入852万元，其中净流入天数为3日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20231128161758844d4c0e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20231128161758844d4c0e&s=b","is_publish_highlight":false}],"profile":{"websiteUrl":"http://wuxixdc.com","stockEarnings":[{"period":"1week","weight":-0.1056},{"period":"1month","weight":0.3981},{"period":"ytd","weight":0.3981}],"compareEarnings":[{"period":"1week","weight":-0.0295},{"period":"1month","weight":-0.0702},{"period":"3month","weight":-0.1026},{"period":"6month","weight":-0.1576},{"period":"1year","weight":-0.1602},{"period":"ytd","weight":-0.1743}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"WuXi XDC Cayman Inc是一家主要从事提供抗体偶联药物（ADC）及更广泛生物偶联药物的合同研究、开发和生产服务（CRDMO）的控股公司。该公司通过两个分部开展其业务。按有偿服务基准的研究服务分部透过有偿服务合约向客户提供研究服务。按全时当量基准提供的研究服务分部提供一个项目小组，该小组的员工在特定时间内专门负责客户的研究。基于生物药和小分子药物，该公司还提供跨领域的综合服务，涵盖生物偶联药物及连接子及有效载荷的发现、工艺开发及药品生产质量管理规范（GMP）生产。该公司在国内外市场开展其业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.222222,"avgChangeRate":0.010265},{"month":2,"riseRate":0.666667,"avgChangeRate":0.058284},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.010372},{"month":4,"riseRate":0.555556,"avgChangeRate":0.03555},{"month":5,"riseRate":0.333333,"avgChangeRate":0.006014},{"month":6,"riseRate":0.4,"avgChangeRate":-0.032735},{"month":7,"riseRate":0.4,"avgChangeRate":0.011785},{"month":8,"riseRate":0.4,"avgChangeRate":-0.114063},{"month":9,"riseRate":0.333333,"avgChangeRate":0.019767},{"month":10,"riseRate":0.777778,"avgChangeRate":0.151657},{"month":11,"riseRate":0.333333,"avgChangeRate":0.008796},{"month":12,"riseRate":0.111111,"avgChangeRate":-0.068876}],"exchange":"SEHK","name":"药明合联","nameEN":"WUXI XDC"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.19.1","shortVersion":"4.19.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药明合联(02268)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药明合联(02268)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药明合联,02268,药明合联股票,药明合联股票老虎,药明合联股票老虎国际,药明合联行情,药明合联股票行情,药明合联股价,药明合联股市,药明合联股票价格,药明合联股票交易,药明合联股票购买,药明合联股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药明合联(02268)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药明合联(02268)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}